Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2016

Description: The report, “Anti-CD279 (PD-1) Antibody-Pipeline Insights, 2016” provides in depth insights on the pipeline drugs and their development activities around the Anti-CD279 (PD-1) Antibody. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. The report Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD279 (PD-1) Antibody. The report Report also assesses the Anti-CD279 (PD-1) Antibody therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Anti-CD279 (PD-1) Antibody
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Anti-CD279 (PD-1) Antibody pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Anti-CD279 (PD-1) Antibody and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete MOA intelligence and complete understanding over therapeutics development for Anti-CD279 (PD-1) Antibody
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Anti-CD279 (PD-1) Antibody pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidencebased Decisions

Contents:
- Anti-CD279 (PD-1) Antibody Overview
- Anti-CD279 (PD-1) Antibody Disease Associated
- Anti-CD279 (PD-1) Antibody Pipeline Therapeutics
- Anti-CD279 (PD-1) Antibody Therapeutics under Development by Companies
Anti-CD279 (PD-1) Antibody Filed and Phase III Products
Comparative Analysis

Anti-CD279 (PD-1) Antibody Phase II Products
Comparative Analysis

Anti-CD279 (PD-1) Antibody Phase I and IND Filed Products
Comparative Analysis

Anti-CD279 (PD-1) Antibody Discovery and Pre-Clinical Stage Products
Comparative Analysis

Drug Candidate Profiles

Anti-CD279 (PD-1) Antibody – Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type

Anti-CD279 (PD-1) Antibody – Discontinued Products
Anti-CD279 (PD-1) Antibody – Dormant Products

Companies Involved in Therapeutics Development for Anti-CD279 (PD-1) Antibody

Appendix
Methodology
Contact Us
Disclaimer

List of Tables
- Number of Products under Development for Anti-CD279 (PD-1) Antibody by Therapy Area, 2016
- Number of Products under Development for Anti-CD279 (PD-1) Antibody, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles

Anti-CD279 (PD-1) Antibody Assessment by Monotherapy Products
Anti-CD279 (PD-1) Antibody Assessment by Combination Products
Anti-CD279 (PD-1) Antibody Assessment by Route of Administration
Anti-CD279 (PD-1) Antibody Assessment by Stage and Route of Administration
Anti-CD279 (PD-1) Antibody Assessment by Molecule Type
Anti-CD279 (PD-1) Antibody Assessment by Stage and Molecule Type
Anti-CD279 (PD-1) Antibody Therapeutics – Discontinued Products
Anti-CD279 (PD-1) Antibody Therapeutics – Dormant Products
Products under Development by Companies, 2016

List of Figures
- Number of Products under Development for Anti-CD279 (PD-1) Antibody by Therapy Area, 2016
- Number of Products under Development for Anti-CD279 (PD-1) Antibody, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016

Anti-CD279 (PD-1) Antibody Assessment by Monotherapy Products
Anti-CD279 (PD-1) Antibody Assessment by Combination Products
Anti-CD279 (PD-1) Antibody Assessment by Route of Administration
Anti-CD279 (PD-1) Antibody Assessment by Stage and Route of Administration
Anti-CD279 (PD-1) Antibody Assessment by Molecule Type
Anti-CD279 (PD-1) Antibody Assessment by Stage and Molecule Type

Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2016
Web Address: http://www.researchandmarkets.com/reports/3534254/
Office Code: SCD2FP27

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 1250</td>
</tr>
<tr>
<td>電子版 (PDF) -</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ____________ Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ______________ Last Name: ______________
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: __________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World